Organogenesis says RCT shows Affinity lifts venous leg ulcer closure rates at weeks 12 and 16

Reuters2026/07/27 20:06

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Organogenesis reported peer-reviewed results from a randomized clinical trial of Affinity in complex venous leg ulcers.
Results were published in the Journal of Wound Care; no separate future presentation was disclosed.
Affinity with standard care improved wound closure outcomes versus standard care alone in hard-to-heal ulcers.
The 206-patient study supports broader clinical evidence across chronic wound types, strengthening the product’s coverage and adoption case.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organogenesis Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607271605PRIMZONEFULLFEED9798643) on July 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Organogenesis says RCT shows Affinity lifts venous leg ulcer closure rates at weeks 12 and 16

You may also like

Crypto prices